June 30, 2022
2 min watch
Save
VIDEO: T-cell redirecting therapies maintain big hold in multiple myeloma space
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope Cancer Center, discusses major developments in multiple myeloma presented at ASCO Annual Meeting.
Krishnan highlights new data on T-cell redirecting therapies, including teclistamab therapies showing high response rates and durable responses, as well as new data showing high response rates on other bispecifics.
Krishnan also discussed the major challenges and unanswered questions moving forward, and directions for future scholarship.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Krishnan reports leadership roles with Sutro Biopharma; research funding to her institution from Janssen; consultant/advisory roles with Bristol Myers Squibb, GlaxoSmithKline and Janssen; speakers bureau roles with Amgen, Bristol Myers Squibb, GlaxoSmithKline and Takeda; and stock ownership in Bristol Myers Squibb.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.